NRx (NRXP) Q2 2026 earnings review
Revenue Flatlines Sequentially While Commercial Prep Sends Losses Surging
NRx has successfully transitioned to a revenue-generating company, but the cost of building its commercial and clinical infrastructure is steep. Q2 net patient service revenue came in at $1.1M, practically flat compared to the implied $1.07M in Q1 2026. Meanwhile, operating expenses are accelerating, surging to $7.6M this quarter as SG&A and R&D costs ramp up ahead of the planned KETAFREE launch. A heavily dilutive $22.3M public offering bolstered the cash balance to $26.7M, securing a 12-month runway. However, with the KETAFREE ANDA delayed by a minor manufacturing attestation and a major clinic acquisition quietly terminated, execution risks are mounting.
🐂 Bull Case
DARPA selected NRx as the prime contractor for the SPARC-TMS trial. This unlocks over $11.5M in non-dilutive funding, potentially expanding NRX-101's addressable market from a sub-million bipolar cohort to 15 million TRD patients.
The FDA identified zero drug or manufacturing deficiencies for KETAFREE, flagging only a luer lock tip issue. With 5 million units already ordered for launch stock, approval seems a matter of 'when,' not 'if.'
🐻 Bear Case
The company's outstanding share count has exploded by 122% YoY (from 19.5M in 25Q2 to 43.2M in 26Q2). The sheer volume of shares and warrants issued cap potential upside for current equity holders.
Despite management's rosy narrative on the call regarding the HOPE Therapeutics network, the 10-Q reveals the company terminated its acquisition of Kadima Medical for cause in August 2026 and is now in arbitration, severely disrupting its vertical integration strategy.
⚖️ Verdict: ⚪
Neutral. Management is securing impressive non-dilutive government contracts and novel intellectual property, but retail investors are bearing the brunt of the capital burden. The disconnect between management's promotional call tone and the quiet termination of the Kadima deal in the 10-Q demands caution.
Key Themes
Omission of Kadima Acquisition Termination
A massive red flag emerged in the 10-Q that was entirely omitted from management's prepared remarks on the earnings call. While CEO Javitt touted the ongoing expansion of the HOPE Therapeutics network, the company quietly disclosed that on August 12, 2026, it terminated the Kadima Purchase Agreement for cause and entered arbitration. This halts a key pillar of their clinic roll-up strategy and directly contradicts the 'exceptionally busy and successful' narrative sold to investors.
Runaway Share Dilution
The cost of survival has been steep. Through a combination of a $20.7M underwritten public offering, an active ATM facility, and convertible note conversions, the company's outstanding share count is accelerating drastically. Total common shares outstanding reached 43.2M at the end of 26Q2, up from 31.7M just six months prior and 19.5M a year ago.
SPARC-TMS Pivot Unlocks DARPA Funding
In a brilliant strategic pivot, NRx combined NRX-101 with robotic Transcranial Magnetic Stimulation (TMS) and secured prime contractor status with DARPA for the SPARC-TMS trial. This shifts the drug's target market from 600k suicidal bipolar patients to over 15M general treatment-resistant depression (TRD) patients, funded by an anticipated $11.5M in non-dilutive military capital.
GeNeuro Acquisition Adds Transformative Assets
NRx successfully acquired the assets of bankrupt Swiss firm GeNeuro SA, gaining a Phase-2-ready monoclonal antibody (Temelimab) and a preclinical ALS asset (GNK-301) co-invented with the NIH. With over $150M in prior European funding already sunk into these assets and new US Congressional grants currently in the bidding phase, this provides a massive, non-dilutive lottery ticket for the pipeline.
Operating Expenses Accelerating
The transition to commercialization is burning cash faster than clinical development did. SG&A expenses surged 73% YoY to $4.7M in 26Q2, driven by commercial team build-outs and clinic integration costs. R&D expenses more than doubled YoY to $2.1M as the company prepared its multiple NDA and ANDA filings.
KETAFREE ANDA Held Up By Plastic
The FDA completed its first-cycle review of KETAFREE (preservative-free ketamine) with no major clinical or manufacturing deficiencies. The sole hold-up is a bureaucratic request for an attestation regarding the vial's luer lock tip. NRx has submitted the paperwork and ordered 5 million doses of launch stock, signaling extreme confidence in a near-term approval.
Other KPIs
Stable sequentially. Represents a full quarter of contribution from the HOPE Therapeutics network (Dura Medical). Growth here is essential to offset cash burn, but Q2 revenue was nearly identical to the implied Q1 revenue of $1.07M, suggesting organic clinic growth is stagnant without further acquisitions.
Reversing significantly. The company recorded a massive $9.8M non-cash charge this quarter due to the increasing fair value of its outstanding warrants (driven by a higher stock price and complex ratchet mechanisms). This heavily distorts the headline Net Loss of $16.5M.
Accelerating dramatically from $7.8M at the end of FY25. The company raised over $32M in net financing activities during the first half of the year, providing vital liquidity to bridge the gap to KETAFREE commercialization.
Guidance
Stable. Management reiterated that current cash of $26.7M, combined with anticipated clinic revenue and opportunistic use of the ATM facility, is sufficient to fund operations for at least one year. No specific numerical revenue or EPS guidance was provided.
Key Questions
Kadima Acquisition Fallout
The 10-Q notes the termination of the Kadima Purchase Agreement for cause and ongoing arbitration. Why was this material event excluded from the earnings call narrative, and how does this impact HOPE's projected clinic network growth?
KETAFREE Timeline
With the luer lock attestation submitted to the FDA, what is the statutory or expected timeline for the agency to complete its review and grant final ANDA approval?
HOPE Clinic Organic Growth
Q2 patient service revenue of $1.1M was effectively flat sequentially compared to Q1. Are the existing Dura clinics operating at full capacity, and what is the strategy to drive organic same-store sales growth?
DARPA Contract Finalization
You've been named prime contractor for SPARC-TMS, but the 10-Q notes funds are subject to completion of contracting. What is the timeline to sign the final contract and begin receiving the $11.5M in non-dilutive capital?